State Street S&P Biotech ETF | XBI

Medium RiskEquity
State Street S&P Biotech ETF
Issued by:State Street
Index : AMEX
Unit Price (NAV) :
Minimum investment: 1 unit
State Street S&P Biotech ETF | XBI

State Street S&P Biotech ETF | XBI


XBI provides exposure to one of the broadest portfolios among US biotech ETFs. Unlike other funds in this segment, XBI is a pure biotech play, with relatively small pharma overlap as we see it. It is one of a handful of biotech ETFs available, offering exposure to a corner of the market that can perform well during periods of consolidation and is capable of big jumps in the event of major drug approvals. The fund’s alternative take on the space earns it a place on our Opportunities List.

XBI tracks an equal-weighted index of US biotechnology stocks. It seeks to track a modified equal weighted index which provides the potential for unconcentrated industry exposure across large, mid and small cap stocks greatly reducing single-name risk and allowing investors to take strategic or tactical positions at a more targeted level than traditional sector based investing. This is also particularly important in the biotech space, where specific companies are capable of turning in big gains over short periods of time. This highly efficient fund, which charges less than competing funds, has a history of beating its index due to revenue from securities lending. It has attracted a large asset base and trades with excellent volume.

About the Fund Manager
State Street Corporation is an American financial services and bank holding company headquartered at One Lincoln Street in Boston with operations worldwide. State Street is ranked among the largest banks in the United States by assets. It is one of the largest asset management companies in the world with trillions under management.

Recommended For


State Street S&P Biotech ETF-12.98%22.72%10.29%19.63%17.78%

Asset Class

Asset type breakdown
Stock US98.96%
Stock non-US0.91%

XBI Holdings - Top 10

NameiWeightage (%)
Ligand Pharmaceuticals Incorporated1.44%
Agios Pharmaceuticals, Inc1.32%
BioCryst Pharmaceuticals, Inc1.24%
Novavax, Inc1.19%
Vir Biotechnology, Inc1.16%
Alexion Pharmaceuticals, Inc1.16%
Dynavax Technologies Corporation1.13%
Allogene Therapeutics, Inc1.11%
Clovis Oncology, Inc1.10%
United Therapeutics Corporation1.09%

XBI Sectors/Industry Breakdown

Sectori% of market value

XBI Countries

Countryi% of market value
North America99.08%
Europe Developed0.92%

Projected Returns

Investment ofper month
gives returns of :
at 15.45% / annum
$in 10 years
for a time period of
Returnsbased on historic SIP returns of 15.45% per annum
$+ 15.45

XBI Summary Data

Total Net Assets $i
Average Mkt Cap Mil $i
Symbol XBI
Exchange ARCX
Asset class Equity

XBI Portfolio Data & Volatility Analysis

Net Expense Ratio 0.35i
Beta 1.22i
Valuations Rates Portfolio PE 16.3295i
3 Year Standard Deviation 30.37i

About State Street

State Street Corporation is an American financial services corporation founded in 1792. State Street has been providing ETFs since 1993. Today State Street provides ETFs across major markets covering different asset classes. State Street prides itself in creating client oriented products.

State Street S&P Biotech ETF | XBI